Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obatoclax in extensive-stage small cell lung cancer
NCT01563601Phase 3Withdrawn
- Sponsor
- Cephalon, Inc.
- Start
- Aug 2012
- Primary completion
- May 2016
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of obatoclax in small cell lung cancer (SCLC), sponsored by Cephalon, Inc.. Planned start Aug 2012; status: withdrawn.
02
Drugs
obatoclax
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01563601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01563601.